Trial
NCT03561090
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Ironwood Pharmaceuticals, Inc.
Collaborators
—
Condition
Gastroesophageal Reflux Disease (GERD)
Intervention
IW-3718
Why stopped
Parallel IW-3718 Phase III trial did not meet pre-specified criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19